Skip to Content
Merck
  • Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on Fonsecaea monophora in vitro.

Photodynamic therapy combined with terbinafine against chromoblastomycosis and the effect of PDT on Fonsecaea monophora in vitro.

Mycopathologia (2014-11-05)
Yongxuan Hu, Xiaowen Huang, Sha Lu, Michael R Hamblin, Eleftherios Mylonakis, Junmin Zhang, Liyan Xi
ABSTRACT

Chromoblastomycosis, a chronic fungal infection of skin and subcutaneous tissue caused by dematiaceous fungi, is associated with low cure and high relapse rates. Among all factors affecting clinical outcome, etiological agents have an important position. In southern China, Fonsecaea pedrosoi and Fonsecaea monophora are main causative agents causing Chromoblastomycosis. We treated one case of chromoblastomycosis by photodynamic therapy (PDT) of 5-aminolevulinic acid (ALA) irradiation combined with terbinafine 250 mg a day. The lesions were improved after two sessions of ALA-PDT treatment, each including nine times, at an interval of 1 week, combined with terbinafine 250 mg/day oral, and clinical improvement could be observed. In the following study, based on the clinical treatment, the effect of PDT and antifungal drugs on this isolate was detected in vitro. It showed sensitivity to terbinafine, itraconazole or voriconazole, and PDT inhibited the growth. Both the clinic and experiments in vitro confirm the good outcome of ALA-PDT applied in the inhibition of F. monophora. It demonstrated that combination of antifungal drugs with ALA-PDT arises as a promising alternative method for the treatment of these refractory cases of chromoblastomycosis.

MATERIALS
Product Number
Brand
Product Description

Voriconazole, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Voriconazole, ≥98% (HPLC)
Supelco
Voriconazole, VETRANAL®, analytical standard
Sigma-Aldrich
Itraconazole, ≥98% (HPLC)
Itraconazole, European Pharmacopoeia (EP) Reference Standard